ALPROLIX
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ALPROLIX
- Generic name
- COAGULATION FACTOR IX (RECOMBINANT), FC FUSION PROTEIN
- Manufacturer
- Bioverativ Therapeutics Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 2fb3fb92-379d-4683-80d6-b06c0a7dc063
- SPL ID
- 24887518-9870-451a-9db5-b03dc5571c19
- Version
- 12
- Effective date
- 2024-05-16
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:47:43
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125444 | derived:openfda.application_number |
| application number | BLA125444 | openfda.application_number | |
| brand name | ALPROLIX | openfda.brand_name | |
| generic name | COAGULATION FACTOR IX (RECOMBINANT), FC FUSION PROTEIN | openfda.generic_name | |
| manufacturer name | Bioverativ Therapeutics Inc. | openfda.manufacturer_name | |
| ndc | package | 71104-955-09 | openfda.package_ndc |
| ndc | package | 71104-953-09 | openfda.package_ndc |
| ndc | package | 71104-922-01 | openfda.package_ndc |
| ndc | package | 71104-966-01 | openfda.package_ndc |
| ndc | package | 71104-977-01 | openfda.package_ndc |
| ndc | package | 71104-952-01 | openfda.package_ndc |
| ndc | package | 71104-911-01 | openfda.package_ndc |
| ndc | package | 71104-045-01 | openfda.package_ndc |
| ndc | package | 71104-933-01 | openfda.package_ndc |
| ndc | package | 71104-944-01 | openfda.package_ndc |
| ndc | package | 71104-954-09 | openfda.package_ndc |
| ndc | package | 71104-951-09 | openfda.package_ndc |
| ndc | package | 71104-956-09 | openfda.package_ndc |
| ndc | product | 71104-911 | openfda.product_ndc |
| ndc | product | 71104-977 | openfda.product_ndc |
| ndc | product | 71104-933 | openfda.product_ndc |
| ndc | product | 71104-922 | openfda.product_ndc |
| ndc | product | 71104-966 | openfda.product_ndc |
| ndc | product | 71104-944 | openfda.product_ndc |
| ndc11 | package | 71104095609 | derived:openfda.package_ndc |
| ndc11 | package | 71104004501 | derived:openfda.package_ndc |
| ndc11 | package | 71104095201 | derived:openfda.package_ndc |
| ndc11 | package | 71104093301 | derived:openfda.package_ndc |
| ndc11 | package | 71104092201 | derived:openfda.package_ndc |
| ndc11 | package | 71104097701 | derived:openfda.package_ndc |
| ndc11 | package | 71104095109 | derived:openfda.package_ndc |
| ndc11 | package | 71104095309 | derived:openfda.package_ndc |
| ndc11 | package | 71104096601 | derived:openfda.package_ndc |
| ndc11 | package | 71104095509 | derived:openfda.package_ndc |
| ndc11 | package | 71104091101 | derived:openfda.package_ndc |
| ndc11 | package | 71104094401 | derived:openfda.package_ndc |
| ndc11 | package | 71104095409 | derived:openfda.package_ndc |
| rxcui | 1666323 | openfda.rxcui | |
| rxcui | 1666320 | openfda.rxcui | |
| spl id | 24887518-9870-451a-9db5-b03dc5571c19 | id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, have been reported. Should symptoms occur, discontinue ALPROLIX and administer appropriate treatment. ( 5.1 ) Neutralizing antibodies (inhibitors) to FIX have been reported with ALPROLIX. Perform an assay that measures Factor IX inhibitor concentration if plasma Factor IX level fails to increase as expected or if bleeding is not controlled with an appropriate dose. ( 5.2 , 5.4 ) The use of Factor IX products has been associated with the development of thromboembolic complications. ( 5.3 ) Nephrotic syndrome has been reported following immune tolerance induction with Factor IX-containing products in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. ( 5.5 ) 5.1 Hypersensitivity Reactions Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ALPROLIX. The presence of inhibitors has been associated with allergic reactions with Factor IX replacement therapies, including with ALPROLIX. Evaluate patients experiencing allergic reactions for the presence of an inhibitor . Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Monitor all patients regularly for the development of inhibitors by appropriate clinical observations and laboratory tests [ see Warnings and Precautions (5.4) ]. Evaluate patients experiencing allergic reactions for the presence of an inhibitor . Closely observe patients for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of exposure to the product. Individuals with Factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with ALPROLIX. 5.3 Thromboembolic Complications The use of Factor IX products has been associated with the development of thromboembolic complications, especially in individuals receiving continuous infusion through a central venous catheter. ALPROLIX should be administered as bolus infusion over several minutes [ see Dosage and Administration (2.3) ]. The safety of ALPROLIX administration by continuous infusion has not been studied . 5.4 Monitoring Laboratory Tests To confirm adequate Factor IX levels have been achieved and maintained, monitor patient plasma Factor IX levels by performing a validated one-stage clotting assay [ see Dosage and Administration (2.1) ] . Factor IX results can be affected by the type of aPTT reagent used. Measurement with a one-stage clotting assay using a kaolin-based aPTT reagent has been shown to result in an underestimation of Factor IX levels. Monitor for the development of Factor IX inhibitors if the expected Factor IX levels in patient plasma are not attained, or if bleeding is not controlled with the recommended dose of ALPROLIX. Perform a Bethesda assay to determine if Factor IX inhibitors are present. 5.5 Nephrotic Syndrome Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥1%) in previously untreated patients (PUPs) were injection site erythema, hypersensitivity, and Factor IX inhibition [ see Warnings and Precautions (5.1) , (5.2) ] . The most common adverse reactions (incidence ≥1%) in previously treated patients (PTPs) were headache, oral paresthesia, and obstructive uropathy. Previously Treated Patients (PTPs): Common adverse reactions (incidence ≥1%) from clinical trials were headache, oral paresthesia, and obstructive uropathy. ( 6 ) Previously Untreated Patients (PUPs): Common adverse reactions (incidence ≥1%) from clinical trial were Factor IX inhibition, injection site erythema, and hypersensitivity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bioverativ Therapeutics Inc. at 1-855-692-5776 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. Previously Treated Patients (PTPs) ALPROLIX has been evaluated in three completed studies (an adult and adolescent study, a pediatric study, and an extension study) in previously treated patients (PTPs) with severe to moderately severe hemophilia B (≤2% endogenous FIX activity). Of the 153 subjects treated, 30 (20%) were children (1 to 11 years of age), 11 (7%) were adolescents (12 to 17 years of age), and 112 (73%) were adults (18 to 71 years of age). There were 126 subjects (82.4%) treated for at least 52 weeks, 107 subjects (69.9%) for at least 104 weeks, and 67 (43.8%) treated for at least 208 weeks. The total number of exposure days (EDs) was 26,106 with a median of 165 (range 1–528) EDs per subject. Adverse events were monitored for a total of 561 subject-years. Adverse reactions (ARs) were reported in 14 of 153 (9.2%) subjects treated with ALPROLIX. They are summarized in Table 3. No subject was withdrawn from the trials due to an adverse reaction. In these PTP trials, no inhibitors were detected and no events of anaphylaxis or vascular thromboembolism were reported. Table 3: Summary of Adverse Reactions in Previously Treated Patients System Organ Class Adverse Reactions Number of Subjects (%) N=153 153 previously treated patients (PTPs) treated with ALPROLIX from the adult and adolescent study, the pediatric study, and the extension study. Nervous system disorders Headache Dizziness Dysgeusia 2 (1.3) 1 (0.7) 1 (0.7) Gastrointestinal disorders Paresthesia oral Breath odor 2 (1.3) 1 (0.7) General disorders and administration site conditions Fatigue Infusion site pain 1 (0.7) 1 (0.7) Cardiac disorders Palpitations 1 (0.7) Renal and urinary disorders Obstructive uropathy Obstructive clot in the urinary collecting system of subjects with hematuria, that resolved with hydration. 2 (1.3) Hematuria 1 (0.7) Renal colic 1 (0.7) Vascular disorders Hypotension 1 (0.7) Metabolism and nutritional disorders Decreased appetite 1 (0.7) Previously Untreated Patients (PUPs) ALPROLIX safety was also evaluated in one completed study (PUPs study) in 33 subjects with hemophilia B (≤2% endogenous FIX activity). Overall, the median number of weeks on treatment was 83.01 (range: 6.7–226.7 weeks). The number of subjects with at least 10 EDs was 28 (84.8%), at least 20 EDs was 26 (78.8%), and at least 50 EDs was 21 (63.6%). The median number of EDs was 76 (range: 1–137) per subject. Adverse events were monitored for a total of 57.51 subject-years. Adverse drug reactions were reported in 2 of 33 (6.1%) subjects treated with ALPROLIX. One subject (3.0%) in the PUP study developed the SAE of Factor IX inhibition and the same subject (3.0%) developed hypersensitivity. One additional subject (3.0%) in the PUP study developed injection site erythema. Immunogenicity Clinical trial subjects were monitored for neutralizing antibodies to Factor IX, and no inhibitors were detected in PTPs during the study. Of 33 PUPs, a total of 1 subject (3.0%) developed a low-titer neutralizing Factor IX inhibitor. The detection of antibodies that are reactive to Factor IX is highly dependent on many factors, including the sensitivity and specificity of the assay, assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. Therefore, it may be misleading to compare the incidence of antibodies to ALPROLIX with the incidence of antibodies to other products. 6.2 Postmarketing Experience The following adverse reactions have been identified during the postapproval use of ALPROLIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Factor IX inhibitor development Immune system disorders: hypersensitivity, including anaphylaxis For additional information, refer to the Warnings and Precautions 5.1 and 5.2.
adverse reactions table
<table ID="t3" width="100%"><caption>Table 3: Summary of Adverse Reactions in Previously Treated Patients</caption><col width="50%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="25%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule">System Organ Class</th><th styleCode="Rrule">Adverse Reactions</th><th styleCode="Rrule">Number of Subjects (%) N=153<footnote>153 previously treated patients (PTPs) treated with ALPROLIX from the adult and adolescent study, the pediatric study, and the extension study. </footnote></th></tr></thead><tbody><tr styleCode="Botrule"><td align="left" valign="top" styleCode="Lrule Rrule"><content styleCode="bold">Nervous system disorders</content></td><td align="center" valign="top" styleCode="Rrule">Headache Dizziness Dysgeusia</td><td align="center" valign="top" styleCode="Rrule">2 (1.3) 1 (0.7) 1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Gastrointestinal disorders</content></td><td align="center" valign="top" styleCode="Botrule Rrule">Paresthesia oral Breath odor</td><td align="center" valign="top" styleCode="Botrule Rrule">2 (1.3) 1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">General disorders and administration site conditions</content></td><td align="center" valign="top" styleCode="Botrule Rrule">Fatigue Infusion site pain</td><td align="center" valign="top" styleCode="Botrule Rrule">1 (0.7) 1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Cardiac disorders</content></td><td align="center" valign="top" styleCode="Botrule Rrule">Palpitations</td><td align="center" valign="top" styleCode="Botrule Rrule">1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Lrule Rrule"><content styleCode="bold">Renal and urinary disorders</content></td><td align="center" valign="top" styleCode="Rrule">Obstructive uropathy<footnote>Obstructive clot in the urinary collecting system of subjects with hematuria, that resolved with hydration.</footnote></td><td align="center" valign="top" styleCode="Rrule">2 (1.3)</td></tr><tr><td align="left" valign="top" styleCode="Lrule Rrule"/><td styleCode="Rrule">Hematuria</td><td align="center" valign="top" styleCode="Rrule">1 (0.7)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"/><td styleCode="Rrule">Renal colic</td><td styleCode="Rrule">1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Vascular disorders</content></td><td align="center" valign="top" styleCode="Botrule Rrule">Hypotension</td><td align="center" valign="top" styleCode="Botrule Rrule">1 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Metabolism and nutritional disorders</content></td><td align="center" valign="top" styleCode="Botrule Rrule">Decreased appetite</td><td align="center" valign="top" styleCode="Botrule Rrule">1 (0.7)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.